| B lymphocyte depletion with the monoclonal antibody rituximab in Graves disease: a controlled pilot study D El Fassi, CH Nielsen, SJ Bonnema, HC Hasselbalch, L Hegedus The Journal of Clinical Endocrinology & Metabolism 92 (5), 1769-1772, 2007 | 181 | 2007 |
| Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves disease D El Fassi, CH Nielsen, J Kjeldsen, O Clemmensen, L Hegedüs Gut 57 (5), 714-715, 2008 | 149 | 2008 |
| Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion DE Fassi, CH Nielsen, HC Hasselbalch, L Hegedüs Thyroid 16 (7), 709-710, 2006 | 130 | 2006 |
| Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study S Verstovsek, AT Gerds, AM Vannucchi, HK Al-Ali, D Lavie, ... The Lancet 401 (10373), 269-280, 2023 | 128 | 2023 |
| Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies D El Fassi, JP Banga, JA Gilbert, C Padoa, L Hegedüs, CH Nielsen Clinical Immunology 130 (3), 252-258, 2009 | 109 | 2009 |
| Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study AL Sørensen, SU Mikkelsen, TA Knudsen, ME Bjørn, CL Andersen, ... haematologica 105 (9), 2262, 2020 | 105 | 2020 |
| The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option D El Fassi, CH Nielsen, HC Hasselbalch, L Hegedüs European journal of endocrinology 154 (5), 623-632, 2006 | 92 | 2006 |
| B-cell depletion with rituximab in the treatment of autoimmune diseases: Graves' ophthalmopathy the latest addition to an expanding family CH Nielsen, DE Fassi, HC Hasselbalch, K Bendtzen, L Hegedüs Expert opinion on biological therapy 7 (7), 1061-1078, 2007 | 65 | 2007 |
| A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2 AL Tølbøll Sørensen, M Rolland, J Hartmann, ZB Harboe, C Roed, ... Blood advances 5 (12), 2569-2574, 2021 | 54 | 2021 |
| Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis SU Mikkelsen, L Kjær, ME Bjørn, TA Knudsen, AL Sørensen, ... Cancer Medicine 7 (8), 3571-3581, 2018 | 51 | 2018 |
| Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial C Fuchs Andersen, M Omar, A Glenthøj, D El Fassi, HJ Møller, ... European Journal of Heart Failure 25 (2), 226-234, 2023 | 44 | 2023 |
| Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Graves disease D El Fassi, O Clemmensen, CH Nielsen, RZ Silkiss, L Hegedus The Journal of Clinical Endocrinology & Metabolism 92 (10), 3762-3763, 2007 | 43 | 2007 |
| Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses TA Knudsen, V Skov, K Stevenson, L Werner, W Duke, C Laurore, ... Blood advances 6 (7), 2107-2119, 2022 | 42 | 2022 |
| Systemic adverse events following rituximab therapy in patients with Graves disease D El Fassi, CH Nielsen, P Junker, HC Hasselbalch, L Hegedüs Journal of endocrinological investigation 34, e163-e167, 2011 | 40 | 2011 |
| Therapeutic cancer vaccination with a peptide derived from the calreticulin exon 9 mutations induces strong cellular immune responses in patients with CALR-mutant chronic
J Handlos Grauslund, MO Holmström, NG Jørgensen, U Klausen, ... Frontiers in oncology 11, 637420, 2021 | 39 | 2021 |
| Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trials JP Banga, CH Nielsen, JA Gilbert, D El Fassi, L Hegedus Thyroid 18 (9), 973-981, 2008 | 30 | 2008 |
| A user's guide to multicolor flow cytometry panels for comprehensive immune profiling S Holmberg-Thyden, K Grønbæk, AO Gang, D El Fassi, SR Hadrup Analytical biochemistry 627, 114210, 2021 | 24 | 2021 |
| Safety and efficacy of combination therapy of interferon-alpha2+ JAK1-2 inhibitor in the Philadelphia-negative chronic myeloproliferative neoplasms. Preliminary results from
SU Mikkelsen, L Kjær, V Skov, ME Bjørn, CL Andersen, OW Bjerrum, ... Blood 126 (23), 824, 2015 | 24 | 2015 |
| Evidence of orbital B and T cell depletion after rituximab therapy in Graves ophthalmopathy JF Nielsen, D El Fassi, CH Nielsen, L Hegedüs, SA Lauer, RZ Silkiss, ... Acta Ophthalmologica 87 (8), 927-929, 2009 | 24 | 2009 |
| Anti-CD20 antibody therapy for B-cell lymphomas RP Taylor, MA Lindorfer, CS Zent N Engl J Med 367 (9), 876-877, 2012 | 22 | 2012 |
